Trial Outcomes & Findings for A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer (NCT NCT03535727)
NCT ID: NCT03535727
Last Updated: 2024-12-31
Results Overview
Dose escalation (phase I portion of the trial only) to determine the MTD in mg/m\^2. Participants received Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
48 participants
Primary outcome timeframe
28 days
Results posted on
2024-12-31
Participant Flow
Participant milestones
| Measure |
Phase 1, Cohort 1, Dose Level 1
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 40 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 2
Gemcitabine 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel 60 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID: PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 3
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 80 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan:20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 4
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel:100 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine:500 PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan:20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 5
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel:125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 2, Dose Level 1
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:40 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 1, Cohort 2, Dose Level 2
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:60 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 1, Cohort 2, Dose Level 3
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:80 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 2 MTD Dose Expansion
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel:125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
3
|
6
|
6
|
6
|
6
|
3
|
3
|
7
|
8
|
|
Overall Study
COMPLETED
|
3
|
6
|
6
|
6
|
6
|
3
|
3
|
7
|
8
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Baseline characteristics by cohort
| Measure |
Phase 1, Cohort 1, Dose Level 1
n=3 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 40 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 2
n=6 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 60 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 3
n=6 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 80 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 4
n=6 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 100 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 5
n=6 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 2, Dose Level 1
n=3 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:40 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 1, Cohort 2, Dose Level 2
n=3 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:60 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 1, Cohort 2, Dose Level 3
n=7 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:80 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 2, MTD Dose Expansion
n=8 Participants
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Total
n=48 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
7 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
27 Participants
n=42 Participants
|
|
Age, Categorical
>=65 years
|
2 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
4 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
4 Participants
n=42 Participants
|
21 Participants
n=42 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
4 Participants
n=24 Participants
|
5 Participants
n=42 Participants
|
25 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
4 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
23 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
3 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
7 Participants
n=24 Participants
|
8 Participants
n=42 Participants
|
48 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
2 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
|
Race (NIH/OMB)
White
|
3 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
6 Participants
n=24 Participants
|
6 Participants
n=42 Participants
|
40 Participants
n=42 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Region of Enrollment
United States
|
3 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
6 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
3 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
7 Participants
n=24 Participants
|
8 Participants
n=42 Participants
|
48 Participants
n=42 Participants
|
|
Eastern Cooperative Oncology Group (ECOG)
ECOG 0
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
|
Eastern Cooperative Oncology Group (ECOG)
ECOG 1
|
3 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
6 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
3 Participants
n=8 Participants
|
5 Participants
n=24 Participants
|
7 Participants
n=42 Participants
|
42 Participants
n=42 Participants
|
PRIMARY outcome
Timeframe: 28 daysPopulation: Cohort 1 cycle schedule was selected for the MTD (Days 1 and 15 of a 28 day cycle)
Dose escalation (phase I portion of the trial only) to determine the MTD in mg/m\^2. Participants received Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Outcome measures
| Measure |
Phase I
n=40 Participants
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Nab-paclitaxel:20, 40, 60, 80, 100,125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle (Cohort 1) or Days 1-14 of a 21 day cycle (Cohort 2)
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
|
|---|---|
|
Maximum Tolerated Dose (MTD) of Gemcitabine.
|
500 mg/m^2
|
PRIMARY outcome
Timeframe: 28 daysPopulation: Cohort 1 cycle schedule was selected for the MTD (Days 1 and 15 of a 28 day cycle)
Dose escalation (phase I portion of the trial only) to determine the MTD in mg/m\^2. Participants received Nab-paclitaxel: 20, 40, 60, 80, 100,125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Outcome measures
| Measure |
Phase I
n=40 Participants
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Nab-paclitaxel:20, 40, 60, 80, 100,125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle (Cohort 1) or Days 1-14 of a 21 day cycle (Cohort 2)
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
|
|---|---|
|
Maximum Tolerated Dose (MTD) of Nab-paclitaxel.
|
125 mg/m^2
|
PRIMARY outcome
Timeframe: 28 daysPopulation: Cohort 1 cycle schedule was selected for the MTD (Days 1-7 and 15-21 of a 28 day cycle)
Dose escalation (phase I portion of the trial only) to determine the MTD in mg for twice daily (BID) use. Participants received Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle (Cohort 1) or Days 1-14 of a 21 day cycle (Cohort 2)
Outcome measures
| Measure |
Phase I
n=40 Participants
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Nab-paclitaxel:20, 40, 60, 80, 100,125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle (Cohort 1) or Days 1-14 of a 21 day cycle (Cohort 2)
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
|
|---|---|
|
Maximum Tolerated Dose (MTD) of Capecitabine.
|
500 mg BID
|
PRIMARY outcome
Timeframe: 28 daysPopulation: Cohort 1 cycle schedule was selected for the MTD (Days 1 and 15 of a 28 day cycle)
Dose escalation (phase I portion of the trial only) to determine the MTD in mg/m\^2. Participants received Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Outcome measures
| Measure |
Phase I
n=40 Participants
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Nab-paclitaxel:20, 40, 60, 80, 100,125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle (Cohort 1) or Days 1-14 of a 21 day cycle (Cohort 2)
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
|
|---|---|
|
Maximum Tolerated Dose (MTD) of Cisplatin.
|
20 mg/m^2
|
PRIMARY outcome
Timeframe: 28 daysPopulation: Cohort 1 cycle schedule was selected for the MTD (Days 1 and 15 of a 28 day cycle)
Dose escalation (phase I portion of the trial only) to determine the MTD in mg/m\^2. Participants received Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Outcome measures
| Measure |
Phase I
n=40 Participants
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Nab-paclitaxel:20, 40, 60, 80, 100,125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle (Cohort 1) or Days 1-14 of a 21 day cycle (Cohort 2)
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
|
|---|---|
|
Maximum Tolerated Dose (MTD) of Irinotecan.
|
20 mg/m^2
|
PRIMARY outcome
Timeframe: 27 monthsPopulation: Per the clinical trial design, PFS analyses included all subjects who received the MTD (Cohort 1, Dose Level 5). Since the enrollment criteria and dose are the same, combining those who are treated at MTD at both phases increase the power and enable to estimate the treatment effect with increased precision. This included the 6 subjects enrolled in the Phase 1 portion of the trial and the 8 subjects enrolled in the Phase 2 portion of the trial for a total of 14 subjects.
PFS is defined as the number of months from the date of first dose to disease progression (progressive disease \[PD\] or relapse from complete response \[CR\] as assessed using RECIST 1.1 criteria) or death due to any cause. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.
Outcome measures
| Measure |
Phase I
n=14 Participants
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Nab-paclitaxel:20, 40, 60, 80, 100,125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle (Cohort 1) or Days 1-14 of a 21 day cycle (Cohort 2)
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
|
|---|---|
|
Progression-free Survival (PFS) Using RECIST 1.1 Criteria
|
5.92 months
Interval 5.52 to
Insufficient number of patients with events.
|
SECONDARY outcome
Timeframe: 27 monthsPopulation: Per the clinical trial design, safety analyses included all subjects who received the MTD (Cohort 1, Dose Level 5). Since the enrollment criteria and dose are the same, combining those who are treated at MTD at both phases enable to estimate the toxicity rate with increased precision. This included the 6 subjects enrolled in the Phase 1 portion of the trial and the 8 subjects enrolled in the Phase 2 portion of the trial for a total of 14 subjects.
Number of patients who received the MTD (Cohort 1, Dose Level 5) that experienced a limiting toxicity. Limiting toxicity was defined as a grade 3 or above treatment-related toxicity, with the following exceptions: 1. Grade 3 anemia that resolves to \< grade 2 within 7 days; 2. Grade 3 thrombocytopenia without clinically significant bleeding that resolves to \< grade 2 within 7 days; 3. Grade 3 or 4 neutropenia that resolves to \<grade 2 within 7 days; 4. Grade 3 or 4 leucopenia/lymphopenia; 5. Grade 3 nausea, vomiting, or diarrhea that resolves to \<grade 2 within 72 hours; 6. Grade 3 or 4 asymptomatic laboratory values that resolve to \< grade 2 within 7 days; 7. Grade 3 dermatologic AEs that are considered mild in severity but only considered grade 3 because of \>30% body surface involvement; 8. Grade 3 fatigue lasting less than 72 hours. This study used the descriptions and grading scales found in the revised NCI CTCAE fV 5.0 for adverse event reporting.
Outcome measures
| Measure |
Phase I
n=14 Participants
Gemcitabine:500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Nab-paclitaxel:20, 40, 60, 80, 100,125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle (Cohort 1) or Days 1-14 of a 21 day cycle (Cohort 2)
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle (Cohort 1) or Days 4 and 11 of a 21 day cycle (Cohort 2)
|
|---|---|
|
Safety of the Combination of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Patients With Untreated Metastatic PDA.
|
3 Participants
|
Adverse Events
Phase 1, Cohort 1, Dose Level 1
Serious events: 0 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Cohort 1, Dose Level 2
Serious events: 2 serious events
Other events: 6 other events
Deaths: 6 deaths
Phase 1, Cohort 1, Dose Level 3
Serious events: 5 serious events
Other events: 6 other events
Deaths: 5 deaths
Phase 1, Cohort 1, Dose Level 4
Serious events: 2 serious events
Other events: 6 other events
Deaths: 6 deaths
Phase 1, Cohort 1, Dose Level 5
Serious events: 4 serious events
Other events: 6 other events
Deaths: 6 deaths
Phase 1, Cohort 2, Dose Level 1
Serious events: 1 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Cohort 2, Dose Level 2
Serious events: 2 serious events
Other events: 3 other events
Deaths: 3 deaths
Phase 1, Cohort 2, Dose Level 3
Serious events: 2 serious events
Other events: 7 other events
Deaths: 7 deaths
Phase 2 MTD Dose Expansion
Serious events: 4 serious events
Other events: 8 other events
Deaths: 7 deaths
Serious adverse events
| Measure |
Phase 1, Cohort 1, Dose Level 1
n=3 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 40 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 2
n=6 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 60 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 3
n=6 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 80 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 4
n=6 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 100 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 5
n=6 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 2, Dose Level 1
n=3 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:40 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 1, Cohort 2, Dose Level 2
n=3 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:60 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 1, Cohort 2, Dose Level 3
n=7 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:80 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 2 MTD Dose Expansion
n=8 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Colonic obstruction
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Diarrhea
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Duodenal ulcer
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Esophageal varices hemorrhage
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Hematemesis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Obstruction gastric
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Fever
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Fatigue
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Disease progression-Death
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Biliary tract infection
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Enterocolitis infectious
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Pseudocyst infection
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Liver abscess
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Stroke
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Syncope
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural hemorrhage
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Thromboembolic event
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
Other adverse events
| Measure |
Phase 1, Cohort 1, Dose Level 1
n=3 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 40 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 2
n=6 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 60 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 3
n=6 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 80 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 4
n=6 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 100 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 1, Dose Level 5
n=6 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
Phase 1, Cohort 2, Dose Level 1
n=3 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:40 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 1, Cohort 2, Dose Level 2
n=3 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:60 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 1, Cohort 2, Dose Level 3
n=7 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Nab-paclitaxel:80 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
Capecitabine:500 mg BID, PO twice daily (BID); Days 1-14 of a 21 day cycle
Cisplatin:20 mg/m\^2, IV over 60 minutes; Days 4 and 11 of a 21 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 4 and 11 of a 21 day cycle
|
Phase 2 MTD Dose Expansion
n=8 participants at risk
Gemcitabine: 500 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Nab-paclitaxel: 125 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
Capecitabine: 500 mg BID, PO twice daily (BID); Days 1-7, 15-21 of a 28 day cycle
Cisplatin: 20 mg/m\^2, IV over 60 minutes; Days 1 and 15 of a 28 day cycle
Irinotecan: 20 mg/m\^2, IV over 30 minutes; Days 1 and 15 of a 28 day cycle
|
|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
Anemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 13 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 9 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 11 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 11 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 24 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
85.7%
6/7 • Number of events 21 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Blood and lymphatic system disorders
Swollen gland
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Blood and lymphatic system disorders
Leukocytosis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Blood and lymphatic system disorders
Lymph node pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Cardiac disorders
Chest pain - cardiac
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Cardiac disorders
Sinus bradycardia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Cardiac disorders
Sinus tachycardia
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 15 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
57.1%
4/7 • Number of events 14 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Ear and labyrinth disorders
Feeling of water/air in right ear
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Ear and labyrinth disorders
Hearing impaired
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Ear and labyrinth disorders
Tinnitus
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Endocrine disorders
Thyromegaly
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Blurred vision
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Cataract
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Dry eye
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Eye pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Floaters
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Periorbital edema
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Vision decreased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Watering eyes
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Double vision
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Conjunctival chalsis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Eye disorders
Transient eye yellowing
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Abdominal pain
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Ascites
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Bloating
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Cheilitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Constipation
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
42.9%
3/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
37.5%
3/8 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Diarrhea
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
83.3%
5/6 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
57.1%
4/7 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
4/8 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Dry mouth
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Fecal incontinence
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Flatulence
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Hemorrhoids
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Mucositis oral
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Nausea
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
42.9%
3/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
62.5%
5/8 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Stomach pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Hernia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
White coating on tongue
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Discolored tongue
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Tongue swollen
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Black stools
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Early satiety
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Stool discoloration
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Loose tooth
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Dumping after meals
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Stools light and floating
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Increased saliva
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Gastrointestinal disorders
Epigastric discomfort
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Chills
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Edema face
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Edema limbs
|
33.3%
1/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Facial pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Fatigue
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
4/8 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Fever
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Gait disturbance
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Hypothermia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Malaise
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
General disorders
Pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Hepatobiliary disorders
Bile duct stenosis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Hepatobiliary disorders
Hepatomegaly
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Hepatobiliary disorders
Hepatosplenomegaly
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Hepatobiliary disorders
Liver Cirrhosis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Hepatobiliary disorders
Portal vein thrombosis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Immune system disorders
Allergic reaction
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Bronchial infection
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Enterocolitis infectious
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Herpes simplex reactivation
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Laryngitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Lung infection
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Otitis media
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Peritoneal infection
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Sinusitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Skin infection
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Thrush
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Upper respiratory infection
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Injury, poisoning and procedural complications
Bruising
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Injury, poisoning and procedural complications
Fracture spinal
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Injury, poisoning and procedural complications
Wound complication
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Activated partial thromboplastin time prolonged
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Alkaline phosphatase increased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Creatinine increased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
International Normalized Ratio increase
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Cocaine metabolite
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Lipase increased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 10 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 19 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
42.9%
3/7 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 10 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
42.9%
3/7 • Number of events 11 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Platelet count decreased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Urine output decreased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Weight gain
|
33.3%
1/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 9 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Weight loss
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 11 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
42.9%
3/7 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
White blood cell decreased
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Acidosis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Anorexia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Investigations
Hyperkalemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
37.5%
3/8 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 13 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 11 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
57.1%
4/7 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
37.5%
3/8 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
37.5%
3/8 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Muscle cramp
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Pseudo gout
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Jaw pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Metabolism and nutrition disorders
Neck pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremities
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps)
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Cognitive disturbance
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Concentration impairment
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Dysgeusia
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
42.9%
3/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Extrapyramidal disorder
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Headache
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
57.1%
4/7 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Aura
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Cold sensitivity
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Jitteriness
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Eye twitch
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Paresthesia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Peripheral motor neuropathy
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
57.1%
4/7 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Seizure
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Stroke
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Transient ischemic attacks
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Tremor
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Psychiatric disorders
Agitation
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Confusion
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Delirium
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Depression
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Insomnia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Hematuria
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Renal cysts
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Renal dysfunction
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Renal calculi
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Urinary frequency
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Urinary tract infection
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Urinary urgency
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Renal and urinary disorders
Urine discoloration
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Allergic rhinitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
42.9%
3/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Hoarseness
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural hemorrhage
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pleuritic pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Postnasal drip
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Bradypnea
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal dryness
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnea
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus drainage
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Dry throat
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhea
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
100.0%
3/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
37.5%
3/8 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Voice alteration
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
83.3%
5/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
83.3%
5/6 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
85.7%
6/7 • Number of events 6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
4/8 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Dry skin
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Nail changes
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Nail discoloration
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysesthesia syndrome
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
57.1%
4/7 • Number of events 8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Rash pustular
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Skin atrophy
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Skin induration
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Skin ulceration
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Lipoma and other skin nodules
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Arterial thromboembolism
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Flushing
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Hematoma
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Hot flashes
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Hypertension
|
33.3%
1/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
4/6 • Number of events 5 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 9 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Hypotension
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
50.0%
3/6 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 4 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Vascular disorders
Thromboembolic event
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
66.7%
2/3 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
25.0%
2/8 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Fungal foot Infection
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Liver abscess
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
COVID-19
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Infections and infestations
Cold sore
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Sternal pain
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Sinus disorder
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Sneezing
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Skin abrasions and injuries
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
14.3%
1/7 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Rash acne form
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Redness and skin sensitivity
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
28.6%
2/7 • Number of events 2 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Skin and subcutaneous tissue disorders
Venous stasis dermatitis of lower extremities
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/8 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
33.3%
1/3 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
16.7%
1/6 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
33.3%
2/6 • Number of events 3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
|
Nervous system disorders
Drop foot
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/6 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/3 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
0.00%
0/7 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
12.5%
1/8 • Number of events 1 • All-Cause Mortality was assessed for up to 51 months for patients in both Phase 1 and Phase 2 portions of the trial. Serious and Other (Not Including Serious) Adverse Events were assessed up to 45 months for patients in both Phase 1 and 2 portions of the trial.
This study used the descriptions and grading scales found in the revised National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for adverse event reporting. During the survival follow-up portion of the trial, patients were evaluated for all-cause mortality past the time frame for treatment and the assessment of adverse events.
|
Additional Information
Dung Le, M.D.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phone: 443-287-0002
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place